CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.
You are attempting to access a website operated by an entity not regulated in the EU. Products and services on this website do not comply with EU laws or ESMA investor-protection standards.
As an EU resident, you cannot proceed to the offshore website.
Please continue on the EU-regulated website to ensure full regulatory protection.
Maandag Sep 22 2025 10:00
2 min.
Medtronic (MDT), a medical device maker, is currently out of favor despite its historically high dividend yield of around 3%. However, the company is actively working to improve its business performance, and stronger results are anticipated. This potential turnaround could position Medtronic as one of the best healthcare stocks to consider today.
Investing in research and development (R&D) is a core aspect of Medtronic's business as a leading medical device manufacturer. However, R&D is inherently a lumpy endeavor, requiring significant time and resources. Part of the current pessimistic view surrounding Medtronic stems from a period of developmental stagnation. This is beginning to change, with new surgical robots and cardiac ablation systems gaining market traction.
This is just the beginning of Medtronic's potential. The company is also focusing on its most profitable business segments. A significant step in this direction is the planned spinoff of its diabetes treatment division, which is expected to be immediately accretive to earnings. This is because the remaining businesses within the healthcare giant (cardiovascular, medical surgical, and neuroscience) boast higher profit margins compared to the diabetes division.
The overarching picture reveals that as new products enter the market, Medtronic's earnings growth could surpass current Wall Street expectations. Increased profit margins should amplify the revenue growth resulting from R&D investments. In essence, investors can benefit from a high dividend yield while awaiting broader market recognition of Medtronic's improving fundamentals. Once this occurs, market sentiment could shift from bearish to bullish.
It's important to remember that R&D investment doesn't guarantee success. There are inherent risks involved in developing new products, including regulatory hurdles and potential lack of commercial viability. However, for a company like Medtronic, continuous R&D investment is crucial for maintaining a competitive edge.
Risk Warning and Disclaimer: This article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform. Trading Contracts for Difference (CFDs) involves high leverage and significant risks. Before making any trading decisions, we recommend consulting a professional financial advisor to assess your financial situation and risk tolerance. Any trading decisions based on this article are at your own risk.
Laatste
Alles bekijkenZaterdag, 18 Oktober 2025
5 min.
Zaterdag, 18 Oktober 2025
5 min.
Zaterdag, 18 Oktober 2025
3 min.
NL
